Department of Breast Oncology, NHO Kysushu Cancer Center, Fukuoka, Japan.
Department of Pathology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Thorac Cancer. 2024 Oct;15(28):2073-2076. doi: 10.1111/1759-7714.15433. Epub 2024 Sep 1.
We present a unique case of metastatic metaplastic breast carcinoma responding dramatically to immunochemotherapy. A 46-year-old Japanese woman with primary metaplastic carcinoma of the breast, which was immunohistochemically confirmed to be triple-negative breast cancer, underwent radical surgery, followed by adjuvant chemotherapy with an anthracycline and a taxane. Since multiple lung metastases were detected two months post-chemotherapy and the primary site was shown to be PD-L1-positive, the immune checkpoint inhibitor (ICI) pembrolizumab plus gemcitabine/carboplatin was initiated. While the treatment was discontinued after 15 days due to suspected drug-induced pneumonitis, the lung metastases significantly shrank with no development of new lesions for three months. The patient remained alive as of approximately 15 months after the recurrence date. This case highlights the potential of immunochemotherapy in treating metaplastic breast carcinomas.
我们报告了一例转移性化生性乳腺癌对免疫化疗反应显著的独特病例。一名 46 岁的日本女性患有原发性化生性乳腺癌，免疫组织化学证实为三阴性乳腺癌，接受了根治性手术，随后接受了蒽环类药物和紫杉烷类药物的辅助化疗。化疗后两个月发现多发性肺转移，且原发部位 PD-L1 阳性，因此开始使用免疫检查点抑制剂（ICI）pembrolizumab 联合吉西他滨/卡铂。由于疑似药物引起的肺炎，治疗在 15 天后停止，但三个月内肺部转移明显缩小，没有新病灶出现。自复发日期以来，患者大约存活了 15 个月。该病例强调了免疫化疗治疗化生性乳腺癌的潜力。
